Smith & Nephew Plc (SNN:NYSE), one of the world's longest-established medical technology companies, traces its roots to 1856, when Thomas James Smith opened a small pharmacy in England; his nephew, Horatio Nelson Smith, later joined to give the firm its enduring name.
Today it describes itself as "a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue," operating under the "Life Unlimited" banner with distribution across more than 100 countries, according to its website.
The business is organized into three global franchises: Orthopedics, Sports Medicine and ENT (ear, nose, and throat), and Advanced Wound Management. In its most recent full year, Smith & Nephew reported revenue of roughly US$6.16 billion, up 6.1%, with operating profit rising to US$794 million and each of its three business units growing more than 5%.
Advanced Wound Management is a cornerstone of the portfolio and the company divides it into three arms — advanced wound care, advanced wound bioactives, and advanced wound devices targeting chronic and hard-to-heal wounds, surgical sites, burns, and pressure injuries, according to the company.
In 2025, the division delivered 6% underlying revenue growth, led by double-digit growth in advanced wound bioactives.
The franchise is anchored by a stable of well-known brands. Its dressing lines include the ALLEVYN family of foam dressings and DURAFIBER; infection management is served by the silver-based ACTICOAT antimicrobial dressings and the cadexomer-iodine IODOSORB/IODOFLEX range; negative-pressure wound therapy runs through the PICO and RENASYS systems; and the bioactives portfolio features the SANTYL collagenase ointment, REGRANEX gel, the OASIS matrix products, and Grafix placental membrane.
In a May 5 release, Smith & Nephew said it planned to highlight its chronic wound management portfolio at the European Wound Management Association (EWMA) Conference in Bremen, Germany, May 6-8.
The Catalyst: The Healthcare Demands of an Aging Population
The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% compound annual growth rate (CAGR), according to MarketsandMarkets.
The report attributed the market's growth to rising rates of chronic diseases, traumatic injuries, burns, and the healthcare demands of an aging population. As healthcare providers, insurers, and manufacturers work to improve patient outcomes while managing long-term costs, wound care has become an increasingly important focus across hospitals, clinics, home healthcare, and long-term care facilities.
The report said demand for wound care products continues to climb as cases of chronic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and trauma-related injuries increase. It notes that delayed wound healing can lead to higher hospitalization costs, greater use of healthcare resources, and increased readmissions, making effective wound management not only a clinical concern but also a financial and operational priority for healthcare organizations.
MarketsandMarkets added that supportive reimbursement policies and government healthcare programs are improving patient access to treatment, while emerging markets are creating new growth opportunities for manufacturers.
Traumatic injuries are one of the key drivers of market expansion, the report said. Citing industry data, it said road traffic accidents cause about 1.3 million deaths each year, while millions more people sustain nonfatal injuries that require wound treatment. It also notes that an estimated 270 million workplace accidents occur globally each year, further increasing demand for wound care products. According to the report, the growing number of trauma cases is boosting the need for advanced dressings, surgical wound care products, biologics, and wound therapy devices.
The report also highlighted the increasing global prevalence of diabetes as another major factor supporting market growth, noting that diabetic foot ulcers remain among the leading reasons for hospitalization in people with diabetes, sustaining long-term demand for specialized wound care therapies and products.
According to a report for Hospital News on January 2 by David Navazio, the industry has posted steady yearly gains over the past five years, and the United States is expected to account for more than 47% of the global market in 2026.
Despite the U.S. maintaining the largest share of the market, the report says international markets are expanding at an even faster pace. It attributes this trend to population aging, broader access to advanced wound care services, and the worldwide adoption of higher standards for wound treatment.
Advances in technology and product development are reshaping the industry as manufacturers work to meet rising demand, Navazio reported, identifying artificial intelligence as one of the most influential developments expected in 2026. He also noted that AI can improve wound assessment, recommend treatment strategies, monitor healing progress, and help prevent future wounds.
Among emerging product trends, the report predicts dressings and other wound care products made with Manuka honey will gain significant traction in 2026. It says the honey, sourced from New Zealand, is valued for its purity and effectiveness and is making a comeback through FDA-approved dressings and topical treatments. The report also highlighted nutrition as an increasingly important component of wound management, emphasizing that adequate protein intake supports tissue growth, cell regeneration, and repair, helping accelerate the healing process.
But avoiding wounds before they develop offers the greatest benefit for patients and healthcare systems, the article said, citing declining diabetes rates in recent years (which experts attribute to improved screening and prevention efforts) as an example of how disease prevention can reduce the incidence of diabetes-related wounds.
Co. Introducing New Wound Management Innovations
Reinforcing its long-term focus on chronic wound care, Smith & Nephew is introducing two new wound management innovations at EWMA in Bremen, both aimed at improving patient outcomes, simplifying treatment, and reducing the demands placed on healthcare professionals. Smith & Nephew said the launch addresses a growing healthcare challenge affecting as many as 14.9 million people across Europe while accounting for up to 4% of healthcare spending.
The company said the new products are designed to support clinicians and patients throughout the continuum of care by improving clinical outcomes and helping patients return to their daily lives.
The new ALLEVYN COMPLETE CARE Foam Dressing features a five-layer construction with specialized mechanisms intended to support wound management while helping prevent pressure ulcers. Smith & Nephew said its enhanced ExuLOCK Technology helps retain exudate and bacteria and releases up to 100 times fewer bacteria than competing foam dressings. The dressing also incorporates the ExuMASK Change Indicator, which helps reduce strikethrough, increases confidence during wound healing, and has been shown to extend wear time compared with other foam dressings. In addition, the ShearDEFENSE Unbonded Layer Technology is engineered to reduce shear forces that can contribute to pressure injuries.
Smith & Nephew said it is also launching the RENASYS EDGE Negative Pressure Wound Therapy System, which emphasizes ease of use while maintaining clinical effectiveness. The lightweight, portable pump is designed to offer intuitive operation and greater discretion for patients while improving convenience. The company said the system significantly enhances wound healing outcomes and achieves an average patient compliance rate of 88% during therapy sessions. Its modular design eliminates the need for annual servicing through low-cost maintenance functionality and supports patient self-care.
"With chronic wound management a strategic priority, we are excited to launch ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE System at EWMA," said Smith & Nephew President of Advanced Wound Management Rohit Kashyap. "Our ongoing commitment to innovation and collaboration continues to drive progress in patient outcomes, as we shape the future of advanced wound care."
Stock Titan on July 27 noted that Cevian Capital II GP Ltd. has disclosed that it beneficially owns 119,179,419 ordinary shares of Smith & Nephew plc, representing a 14.18% stake in the medical technology company based on shares outstanding as of July 23. The filing states that Cevian has sole authority to vote and dispose of all of those shares.
According to the filing, the Cevian Funds acquired the shares for a combined purchase price of approximately US$1,673,390,427, using general working capital to finance the investment.
According to a review of the stock by Simply Wall St. in a piece published by Yahoo! Finance on April 27, Smith & Nephew has delivered strong earnings growth in recent years. Because share prices generally tend to reflect earnings per share (EPS) performance over the long run, sustained EPS expansion is often viewed as an important indicator of corporate health. Over the past three years, the company has posted compound annual EPS growth of 42%, an impressive pace that, while unlikely to continue indefinitely, deserves investors' attention, the article said.
Another measure of the company's performance comes from examining earnings before interest and tax (EBIT) margins alongside revenue growth. Smith & Nephew's EBIT margin remained relatively stable over the past year, while revenue increased 6.1% to US$6.2 billion, a combination that reflects continued top-line expansion.
Streetwise Ownership Overview*
Smith & Nephew Plc (SNN:NYSE)
The analysis also considers whether management's interests are aligned with those of shareholders. With a market capitalization of £9.9 billion, insiders are not expected to own a significant percentage of the company's stock. Even so, insiders collectively hold shares valued at approximately US$12 million, reflecting meaningful financial exposure that may reinforce confidence in the company's strategy. Although that ownership represents only about 0.1% of outstanding shares, it still gives insiders a substantial incentive to pursue initiatives that benefit shareholders.
"Smith & Nephew's earnings per share growth have been climbing higher at an appreciable rate," the article noted. "That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. Based on the sum of its parts, we definitely think it's worth watching Smith & Nephew very closely. Don't forget that there may still be risks."
Based on recommendations issued by nine Wall Street analysts over the past 12 months, Smith & Nephew has earned a consensus rating of "Hold," according to MarketBeat. Among those analysts, five recommend holding the stock, while the remaining four have assigned it a buy rating, reflecting a generally balanced outlook with a modestly positive tilt toward the shares.
1Less than 1% of the company is held by insiders and management and about 10% is held by institutions. The rest is retail.
Its market cap is US$13.01 billion with 420.26 million shares outstanding. It trades in a 52-week range of US$28.56 and US$38.79.
Clyra Medical Technologies
If Smith & Nephew represents the established scale of the wound care market, Clyra Medical Technologies represents a smaller, focused challenger now testing its edges.
The company is about 48% owned by the publicly traded company BioLargo Inc. (BLGO:OTCQX) and is commercializing a wound care platform built around a single patented chemistry: Copper-Iodine Complex Solution, or CICS, marketed as Clyrasept.
Its lead product, ViaCLYR, is an FDA 510(k)-cleared wound irrigation solution indicated for cleansing, irrigating, and debriding dermal wounds and burns and for moistening and lubricating absorbent wound dressings. The clearance covers use on a wide range of wound types — including first- and second-degree burns, Stage I–IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions.
What distinguishes the technology is a mechanism the company calls "chemistry on demand." Rather than dumping a large, tissue-damaging dose of antiseptic onto a wound all at once, ViaCLYR holds a reservoir of roughly 250 ppm of iodine potential and releases only small amounts of free iodine as pathogens appear, keeping the remainder in reserve for later contamination. According to Clyra's in vitro technical summary, this is what underpins the solution's antimicrobial persistence as a preservative in solution: when researchers re-challenged the solution with fresh doses of bacteria at 10 minutes, 4, 24, 48, and 72 hours without adding any new solution, it continued to neutralize them at every interval, the company said.
The kill data are fast and broad — in laboratory time-kill testing against 19 organisms, essentially all standard bacteria and fungi were neutralized within one minute, including drug-resistant threats such as MRSA, VRE, Acinetobacter baumannii, and the hard-to-kill fungus Candida auris.
The second pillar of Clyra's pitch is safety. Many effective antiseptics are also toxic to the very cells a wound needs to heal, forcing clinicians to choose between killing bacteria and protecting tissue. In comparative cytotoxicity testing, ViaCLYR passed, indicating it does not harm healthy dermal cells. Several standard-of-care agents have failed the same assessment, including Dakin's solution, chlorhexidine gluconate, hydrogen peroxide, and povidone iodine, Clyra said.
These kill-rate and persistence figures come from in vitro laboratory testing and characterize the antimicrobial activity of the solution as a preservative; they are not part of ViaCLYR's FDA clearance, which does not include a claim that the product kills pathogens in the wound or treats or prevents infection.
That combination — potent, resistance-free, broad-spectrum kill without cytotoxicity, and no rinse required — is precisely the gap in the incumbent toolkit that Clyra said it is targeting.
Clyra Chief Executive Officer Steve Harrison illustrated this with a story about a leading burn surgeon whose competitor's product "lasts about two minutes," and whose only fix was more dressing changes.
"More labor, more cost, more time, more pain and suffering to make (the) product work," he told Streetwise Reports. "We're not asking any of that... a product that doesn't need to generate more dressing changes, more suffering, more pain, more crying, more bleeding, and more cost and expense."
The company said it also helps finance-strapped hospitals with its efficiency, which frees up doctors and nurses to treat more patients.
Harrison noted that Clyra is in negotiations with several large U.S. health systems on pricing driven by physician enthusiasm.
Technical Analyst: Clyra Is a Standout Asset for Co.
2On March 11, Technical Analyst John Newell of John Newell & Associates published an in-depth assessment of parent company BioLargo for Streetwise Reports, highlighting the company's progress in the healthcare sector through Clyra.
Newell said BioLargo has pursued a disciplined strategy of developing its proprietary technologies through extensive scientific validation while partnering with established organizations to expand the commercial reach of its innovations. He noted that the company's portfolio spans advanced water treatment, environmental remediation, air quality management, energy storage, and medical technology solutions.
According to Newell, Clyra is one of BioLargo's standout healthcare assets. It uses copper-iodine antimicrobial technologies that remain effective for as long as 72 hours while being non-cytotoxic, making them well-suited for wound care and infection control. He added that Clyra's lead product, ViaCLYR™, has received FDA 510(k) clearance, allowing it to be marketed through established medical device distribution channels. Newell also noted that the technology is protected by approximately 40 issued and pending patents and is offered in multiple formats, including liquids, powders, hydrogels, and antimicrobial dressings.
Based on the potential of BioLargo's technology platforms, Newell assigned the company a Speculative Buy rating. He praised BioLargo's deliberate commercialization strategy and emphasis on strategic partnerships, saying those efforts position the company to benefit from growing demand for advanced healthcare technologies and sustainable energy storage solutions.
On May 18, Oak Ridge Financial Analyst Richard Ryan described BioLargo's business model as a "hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan reaffirmed his Buy rating on the shares, stating that BioLargo's strategy of commercializing technologies through its operating subsidiaries helps diversify risk while allowing the company to retain significant ownership positions across multiple businesses serving high-growth markets.
Common Investor Questions
What is ViaCLYR? ViaCLYR is Clyra Medical Technologies' lead product — an FDA 510(k)-cleared wound irrigation and management solution built on its patented Copper-Iodine Complex Solution (CICS), branded Clyrasept. It's used to clean, irrigate, moisturize, and debride acute and chronic wounds.
How does it work? It uses a dual mechanism: the copper-iodine chemistry neutralizes pathogens in solution, and the physical flushing rinses away the dead microbes and debris. Its "chemistry on demand" design holds a reservoir of iodine potential (~250 ppm) and releases only small amounts of free iodine as pathogens appear, which is the basis for its claim of sustained, 72-hour antimicrobial persistence.
What makes it different from existing wound-care products?
Two things. Persistence — it stays active in the wound for up to 72 hours rather than minutes, reducing the need for repeated dressing changes. And safety — in cytotoxicity testing it did not harm the healthy cells needed for healing, whereas several common antiseptics (Dakin's solution, chlorhexidine, hydrogen peroxide, povidone iodine) failed that same test.
How big is the wound-care market opportunity? The global wound care market is projected to grow from about US$22.22 billion in 2025 to US$30.48 billion by 2030 (6.5% CAGR), driven by aging populations, diabetes, and chronic wounds.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals and Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical Technologies.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
2. Disclosure for the quote from the John Newell article published on March 11, 2026
- For the quoted article (published on March 11, 2026), BioLargo has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
